Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLG AMLM26 INTERCEPT: MBG453 + Azacitidine in AML
NCT06664879Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sabatolimab in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2024; status: active, not recruiting.
02
Drugs
sabatolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06664879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664879.